NCT02859961View on ClinicalTrials.gov

Study of PRO 140 SC As Single Agent Maintenance Therapy in Virally Suppressed Subjects with CCR5-tropic HIV-1 Infection

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

556

Participants

Timeline

Start Date

July 11, 2016

Primary Completion Date

September 16, 2020

Study Completion Date

December 7, 2020

Conditions
HIV
Interventions
DRUG

PRO 140 (350 mg)

PRO 140 350 mg (175 mg/mL) SC injection per week

DRUG

PRO 140 (525 mg)

PRO 140 525 mg (175 mg/mL) SC injection per week

DRUG

PRO 140 (700 mg)

PRO 140 700 mg (175 mg/mL) SC injection per week

Trial Locations (12)

10011

CD03 Investigational site, New York

13210

CD03 Investigational site, Syracuse

32803

CD03 Investigational site, Orlando

33401

CD03 Investigational site, West Palm Beach

34982

CD03 Investigational site, Ft. Pierce

67214

CD03 Investigational site, Wichita

89109

CD03 Investigational site, Las Vegas

91942

CD03 Investigational site, La Mesa

92262

CD03 Investigational site, Palm Springs

94115

CD03 Investigational site, San Francisco

06510

CD03 Investigational site, New Haven

06850

CD03 Investigational site, Norwalk

Sponsors

Lead Sponsor

CytoDyn, Inc.
All Listed Sponsors
lead

CytoDyn, Inc.

INDUSTRY

NCT02859961 - Study of PRO 140 SC As Single Agent Maintenance Therapy in Virally Suppressed Subjects with CCR5-tropic HIV-1 Infection | Biotech Hunter | Biotech Hunter